Outcome of Board Meeting
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Eyantra Ventures approved standalone and consolidated unaudited financial results for Q3 and 9 months ended December 31, 2025. Standalone revenue surged to Rs. 2,162.55 lakhs in Q3 (vs Rs. 981 lakhs a year ago) and Rs. 5,404.25 lakhs for 9M (vs Rs. 2,111.89 lakhs), driven by merchandise sales and IT services. However, standalone net profit collapsed to Rs. 1.98 lakhs in Q3 (vs Rs. 45.74 lakhs) and Rs. 11.91 lakhs for 9M (vs Rs. 161.33 lakhs) due to higher employee and operating costs. On a consolidated basis, the company reported a net loss of Rs. 367.87 lakhs in Q3 and Rs. 1,153.02 lakhs for 9M, largely driven by losses from the newly consolidated subsidiary Neuro and Spine Associates (hospital and pharmacy business). The Board also appointed M/s SKSM & Associates as Internal Auditor for FY 2026-27. The statutory auditor PRSV & Co. LLP issued an unmodified review report.
Strong top-line growth driven by acquisitions and core business expansion is positive, but sharply falling standalone profits and a consolidated loss raise concerns about margin pressure and integration costs of the hospital/pharmacy subsidiary. Shareholders should watch whether the new healthcare segment turns profitable and if standalone margins recover, as the consolidated EPS swung deeply negative to Rs. (30.72) for 9M FY26.